BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 16175929)

  • 1. Modulation of intra-pulmonary TGF-beta expression by mycophenolate mofetil in lupus prone MRL/lpr mice.
    Guo H; Leung JC; Chan LY; Lui SL; Tsang AW; Lai KN
    Lupus; 2005; 14(8):583-92. PubMed ID: 16175929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice.
    Lui SL; Tsang R; Wong D; Chan KW; Chan TM; Fung PC; Lai KN
    Lupus; 2002; 11(7):411-8. PubMed ID: 12195781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycophenolate mofetil reduces renal cortical inducible nitric oxide synthase mRNA expression and diminishes glomerulosclerosis in MRL/lpr mice.
    Yu CC; Yang CW; Wu MS; Ko YC; Huang CT; Hong JJ; Huang CC
    J Lab Clin Med; 2001 Jul; 138(1):69-77. PubMed ID: 11433230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct effects of mycophenolate mofetil and cyclophosphamide on renal fibrosis in NZBWF1/J mice.
    Yung S; Zhang Q; Chau MK; Chan TM
    Autoimmunity; 2015; 48(7):471-87. PubMed ID: 26099989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attenuation of murine lupus nephritis by mycophenolate mofetil.
    Van Bruggen MC; Walgreen B; Rijke TP; Berden JH
    J Am Soc Nephrol; 1998 Aug; 9(8):1407-15. PubMed ID: 9697662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An ACE inhibitor reduces Th2 cytokines and TGF-beta1 and TGF-beta2 isoforms in murine lupus nephritis.
    De Albuquerque DA; Saxena V; Adams DE; Boivin GP; Brunner HI; Witte DP; Singh RR
    Kidney Int; 2004 Mar; 65(3):846-59. PubMed ID: 14871404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycophenolate mofetil ameliorates perivascular T lymphocyte inflammation and reduces the double-negative T cell population in SLE-prone MRLlpr/lpr mice.
    Jonsson CA; Erlandsson M; Svensson L; Mölne J; Carlsten H
    Cell Immunol; 1999 Nov; 197(2):136-44. PubMed ID: 10607431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renoprotective effects of combination of angiotensin converting enzyme inhibitor with mycophenolate mofetil in diabetic rats.
    Wu YG; Lin H; Qian H; Zhao M; Qi XM; Wu GZ; Lin ST
    Inflamm Res; 2006 May; 55(5):192-9. PubMed ID: 16830106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of autoimmune disease in the MRL-lpr/lpr mouse by IL-2 and TGF-beta1 gene therapy using attenuated Salmonella typhimurium as gene carrier.
    Huggins ML; Huang FP; Xu D; Lindop G; Stott DI
    Lupus; 1999; 8(1):29-38. PubMed ID: 10025597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ac-SDKP ameliorates the progression of lupus nephritis in MRL/lpr mice.
    Tan H; Zhao J; Wang S; Zhang L; Wang H; Huang B; Liang Y; Yu X; Yang N
    Int Immunopharmacol; 2012 Dec; 14(4):401-9. PubMed ID: 22922317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLlpr/lpr mice.
    Jonsson CA; Svensson L; Carlsten H
    Clin Exp Immunol; 1999 Jun; 116(3):534-41. PubMed ID: 10361247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with sirolimus and mycophenolate mofetil: effects on the kidney and on transforming growth factor-beta1.
    Shihab FS; Bennett WM; Yi H; Choi SO; Andoh TF
    Transplantation; 2004 Mar; 77(5):683-6. PubMed ID: 15021829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Tissue-Tended Mycophenolate-Modified Nanoparticle Alleviates Systemic Lupus Erythematosus in MRL/
    Jiang B; Zhang Y; Li Y; Chen Y; Sha S; Zhao L; Li D; Wen J; Lan J; Lou Y; Su H; Zhang C; Zhu J; Tao J
    Int J Nanomedicine; 2022; 17():3251-3267. PubMed ID: 35924257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retinoic acid treatment protects MRL/lpr lupus mice from the development of glomerular disease.
    Pérez de Lema G; Lucio-Cazaña FJ; Molina A; Luckow B; Schmid H; de Wit C; Moreno-Manzano V; Banas B; Mampaso F; Schlöndorff D
    Kidney Int; 2004 Sep; 66(3):1018-28. PubMed ID: 15327395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High expression of interleukin-1beta in the corneal epithelium of MRL/lpr mice is under the control of their genetic background.
    Okamoto M; Takagi M; Kutsuna M; Hara Y; Nishihara M; Zhang MC; Matsuda T; Sakanaka M; Okamoto S; Nose M; Ohashi Y
    Clin Exp Immunol; 2004 May; 136(2):239-44. PubMed ID: 15086386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus.
    Bengtsson AA; Sturfelt G; Lood C; Rönnblom L; van Vollenhoven RF; Axelsson B; Sparre B; Tuvesson H; Ohman MW; Leanderson T
    Arthritis Rheum; 2012 May; 64(5):1579-88. PubMed ID: 22131101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.
    Okazaki H; Hirata D; Kamimura T; Sato H; Iwamoto M; Yoshio T; Masuyama J; Fujimura A; Kobayashi E; Kano S; Minota S
    J Rheumatol; 2002 Apr; 29(4):707-16. PubMed ID: 11950011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of early renal injury by mycophenolate mofetil and its mechanism in experimental diabetes.
    Wu YG; Lin H; Qi XM; Wu GZ; Qian H; Zhao M; Shen JJ; Lin ST
    Int Immunopharmacol; 2006 Mar; 6(3):445-53. PubMed ID: 16428080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice.
    Kulkarni O; Eulberg D; Selve N; Zöllner S; Allam R; Pawar RD; Pfeiffer S; Segerer S; Klussmann S; Anders HJ
    J Pharmacol Exp Ther; 2009 Feb; 328(2):371-7. PubMed ID: 18997060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice.
    Anders HJ; Belemezova E; Eis V; Segerer S; Vielhauer V; Perez de Lema G; Kretzler M; Cohen CD; Frink M; Horuk R; Hudkins KL; Alpers CE; Mampaso F; Schlöndorff D
    J Am Soc Nephrol; 2004 Jun; 15(6):1504-13. PubMed ID: 15153561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.